Medicure Inc. (MPH) Completes Enrollment in Phase 3 PNPO Trial

Medicure completed enrollment of 10 patients in its MEND-PNPO Phase 3 study of MC-1 for PNPO deficiency. The program has FDA Orphan, Rare Pediatric Disease, and Fast Track designations; MC-1 is not FDA-approved.Material DetailsContext by AI AnalystThis is an execution milestone in an ultra-rare epi…